UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(Registrant’s telephone number including area code) 336 -229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Exchange Act.
Title of Each Class Trading Symbol Name of exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders | ||||
The 2024 Annual Meeting of Shareholders (the “Annual Meeting”) of Laboratory Corporation of America Holdings (the “Company”) was held on May 14, 2024. As of March 20, 2024, the date of record for determining the Company’s shareholders entitled to vote on the proposals presented at the Annual Meeting, there were 84,125,885 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting. The holders of 77,058,074 shares of the Company’s issued and outstanding common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum. The proposals presented at the Annual Meeting are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2024 (the “Proxy Statement”). The vote results detailed below represent final results as certified by the Inspector of Elections.
Proposal 1.
The Company’s shareholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for the term expiring at the 2025 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation, or removal:
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||||||||||||||
Adam H. Schechter | 66,696,331 | 3,866,647 | 240,211 | 6,254,885 | |||||||||||||||||||
Kerrii B. Anderson | 65,317,209 | 5,379,339 | 106,641 | 6,254,885 | |||||||||||||||||||
Jeffrey A. Davis | 70,603,583 | 89,968 | 109,638 | 6,254,885 | |||||||||||||||||||
D. Gary Gilliland, M.D., Ph.D. | 70,026,112 | 666,813 | 110,264 | 6,254,885 | |||||||||||||||||||
Kirsten M. Kliphouse | 70,637,639 | 59,699 | 105,851 | 6,254,885 | |||||||||||||||||||
Garheng Kong, M.D., Ph.D. | 68,880,113 | 1,816,173 | 106,903 | 6,254,885 | |||||||||||||||||||
Peter M. Neupert | 67,187,525 | 3,507,269 | 108,395 | 6,254,885 | |||||||||||||||||||
Richelle P. Parham | 68,403,353 | 2,291,498 | 108,338 | 6,254,885 | |||||||||||||||||||
Paul B. Rothman, M.D. | 70,622,022 | 73,434 | 107,733 | 6,254,885 | |||||||||||||||||||
Kathryn E. Wengel | 45,457,646 | 25,179,174 | 166,369 | 6,254,885 | |||||||||||||||||||
Proposal 2.
The Company’s shareholders approved in an advisory (non-binding) vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 65,007,331 | 5,566,884 | 228,974 | 6,254,885 | ||||||||
Proposal 3.
The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The votes regarding this proposal were as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 76,120,507 | 832,250 | 105,317 | 0 | ||||||||
Proposal 4.
The Company’s shareholders did not approve the shareholder proposal requesting adoption of a policy regarding shareholder opportunity to vote on excessive golden parachutes. The votes regarding this proposal were as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 5,219,140 | 65,530,226 | 53,823 | 6,254,885 | ||||||||
Proposal 5.
The Company’s shareholders did not approve the shareholder proposal seeking an annual Board report on the transport of nonhuman primates within the United States. The votes regarding this proposal were as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 5,787,586 | 64,071,818 | 943,785 | 6,254,885 | ||||||||
Proposal 6.
The shareholder proposal requesting that the Board issue a report on the risks of fulfilling information requests was withdrawn by the proponent and not presented at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
| By: | /s/ SANDRA VAN DER VAART | |||||||
| Sandra van der Vaart | ||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||||
May 16, 2024